计划状态
招聘阶段
第二阶段允许先接受免疫治疗
没有CRC 指导的试验
是药物
Placebo, QBECO标签
MSI-H/ MMRd、MSS/ MMRp| 地点 | 位置状态 |
|---|---|
| 加拿大 | |
|
Hamilton Health Science Centre Hamilton, Ontario |
尚未招聘 |
|
London Health Science Centre London, Ontario |
尚未招聘 |
|
The Ottawa Hospital Ottawa, Ontario |
招聘 |
|
Sunnybrook Health Science Centre Toronto, Ontario L4H1Z9 |
招聘 |
联系方式
纳入标准
纳入标准
* Adults aged 18 years or older at time of enrollment.
* Pathologic diagnosis of colorectal carcinoma with clinical diagnosis of liver metastases
* Planned to undergo resection of liver lesions for complete clearance of all visible metastatic disease. This will include those who may undergo synchronous resection of the primary colorectal cancer and/or those who may receive a combination of surgery and ablation to treat all lesions.
* Computerized Tomography (CT) of the chest, abdomen, and pelvis with intravenous (IV) contrast within 6 weeks prior to enrollment.
* MRI of the liver within 6 weeks prior to enrollment OR within 6 weeks prior to starting neoadjuvant chemotherapy (for patients treated with chemotherapy).
* Planned to receive the last dose of neoadjuvant chemotherapy at least 25 days prior to surgery (for patients treated with neoadjuvant chemotherapy).
* Agree to comply with the contraceptive requirements of the protocol when applicable
* Willing and able to either perform subcutaneous injections according to the study protocol, or receive the injections from a caregiver delegated by the participant.
* Able to provide informed consent or has a substitute decision maker capable of providing consent on their behalf.
排除标准
排除标准：
* Prior or current evidence of extrahepatic metastases. Patients with small (
